Answer
Mylotarg (gemtuzumab ozogamicin), combined with daunorubicin and cytarabine, is indicated for patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia, excluding acute promyelocytic leukaemia.
Sources for this answer
- MYLOTARG 5mg powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.1 Therapeutic Indications · Version 13Document updated
Sources checked